Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Nov 1;36(6):438-444.
doi: 10.1097/BOR.0000000000001041. Epub 2024 Aug 13.

From traditional to targeted: the changing trajectory of therapies in dermatomyositis

Rochelle L Castillo  1 , Kimberly Hashemi  1 , Elizabeth Rainone  1 , Katharina S Shaw  2   3 , Ruth Ann Vleugels  1
Affiliations
Review

From traditional to targeted: the changing trajectory of therapies in dermatomyositis

Rochelle L Castillo et al. Curr Opin Rheumatol. .

Abstract

Purpose of review: New breakthroughs in our understanding of dermatomyositis (DM) have spawned the recent development of novel agents that specifically target key drivers in DM immunopathogenesis. This review aims to provide a comprehensive overview of new and forthcoming therapies for DM and to highlight their mechanisms of action, best evidence to date, and potential impact on disease management.

Recent findings: Strategies that either counteract dysregulated interferon signaling [via the inhibition of interferon β, the type I interferon receptor subunit 1 (IFNAR1), or janus kinase (JAK)-signal transducer and activator of transcription (STAT) transduction] or induce durable autoreactive B cell depletion through chimeric antigen receptor (CAR) T-cell therapy appear to hold the most promise for sustained remission in DM.

Summary: The trajectory of DM treatments is rapidly evolving, fueled by the unparalleled insights provided by multiomic studies and big data analysis pipelines. Targeted therapies that maximize both efficacy and safety have the potential to complement or replace traditional immunosuppressives and revolutionize the approach to the management of DM.

PubMed Disclaimer

References

    1. Lundberg IE, Fujimoto M, Vencovsky J, et al. Idiopathic inflammatory myopathies. Nat Rev Dis Prim 2021; 7:86.
    1. Curtis AC, Heckaman JH, Wheeler AH. Study of the autoimmune reaction in dermatomyositis. JAMA 1961; 178:571–573.
    1. Tabata MM, Hodgkinson LM, Wu TT, et al. The type I interferon signature reflects multiple phenotypic and activity measures in dermatomyositis. Arthritis Rheumatol 2023; 75:1842–1849.
    1. Huard C, Gullà SV, Bennett DV, et al. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon ( in dermatomyositis. Br J Dermatol 2017; 176:1224–1230.
    1. Qian J, Li R, Chen Z, et al. Type I interferon score is associated with the severity and poor prognosis in anti-MDA5 antibody-positive dermatomyositis patients. Front Immunol 2023; 14:1151695.

MeSH terms